General Information of Drug (ID: DM5Y2M8)

Drug Name
BENZIL Drug Info
Synonyms
BENZIL; 134-81-6; Diphenylethanedione; Dibenzoyl; Diphenylglyoxal; 1,2-Diphenylethane-1,2-dione; Bibenzoyl; Ethanedione, diphenyl-; 1,2-Diphenylethanedione; diphenylethane-1,2-dione; Glyoxal, diphenyl-; Diphenyldiketon; 1,2-ethanedione, 1,2-diphenyl-; Diphenyl-alpha,beta-diketone; NSC 220315; CCRIS 6179; UNII-S85X61172J; EINECS 205-157-0; WY-20910; AI3-00898; CHEMBL189886; CHEBI:51507; 1,2-diphenyl-ethane-1,2-dione; Diphenyl-.alpha.,.beta.-diketone; WURBFLDFSFBTLW-UHFFFAOYSA-N; C14H10O2; MFCD00003080; S85X61172J; 1,2-dione; Benzil, 99+
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
8651
ChEBI ID
CHEMBL51507
CAS Number
CAS 134-81-6
TTD Drug ID
DM5Y2M8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [3]
PACTIMIBE DM0NZDT Arteriosclerosis BD40 Phase 2/3 [4]
K-604 DMQVN6P Arteriosclerosis BD40 Phase 2 [5]
Eldacimibe DML7WP0 Hyperlipidaemia 5C80 Phase 2 [6]
GR148672X DM7W6YN Acute lymphoblastic leukaemia 2A85 Clinical trial [7]
Avasimibe DMFG4OM Peripheral vascular disease BD4Z Discontinued in Phase 3 [8]
E-5324 DM562BM Hyperlipidaemia 5C80 Discontinued in Phase 2 [9]
RP-64477 DMTQ3BS Hyperlipidaemia 5C80 Discontinued in Phase 2 [10]
CI-976 DMBO28J Hyperlipidaemia 5C80 Discontinued in Phase 2 [11]
CL-283796 DM7LIDT Hyperlipidaemia 5C80 Discontinued in Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [13]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [14]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [15]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [16]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [17]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [18]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [19]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [20]
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [21]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [22]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Liver carboxylesterase (CES1) TTMF541 EST1_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Dehydrogenase/reductase SDR family member 7 (DHRS7) OTV729DT DHRS7_HUMAN Biotransformations [2]

References

1 Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30.
2 Biochemical properties of human dehydrogenase/reductase (SDR family) member 7. Chem Biol Interact. 2014 Jan 25;207:52-7. doi: 10.1016/j.cbi.2013.11.003. Epub 2013 Nov 16.
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33.
5 A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7.
6 Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
8 New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97(2):59-66.
9 Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis. 1994 Jun;107(2):187-201.
10 RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol. 1996 Feb 23;51(4):413-21.
11 Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells. Atherosclerosis. 1995 Jan 6;112(1):7-17.
12 ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys. J Lipid Res. 1995 Jun;36(6):1199-210.
13 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
14 Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
15 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
16 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
17 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
18 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
19 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
20 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
21 Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
22 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.